Elderly woman recovering from hip fracture applies testosterone gel and exercises with therapist in bright rehab setting.
Elderly woman recovering from hip fracture applies testosterone gel and exercises with therapist in bright rehab setting.
Àwòrán tí AI ṣe

Testosterone gel plus exercise may limit visceral fat gain in older women recovering from hip fractures

Àwòrán tí AI ṣe
Ti ṣayẹwo fun ododo

A University of Connecticut-led clinical trial found that older women recovering from a recent hip fracture who used a topical testosterone gel alongside a structured exercise program did not experience the typical rise in visceral abdominal fat seen during recovery. Researchers followed participants for six months and assessed body composition with imaging scans.

As people age, body fat can shift from just under the skin to deeper deposits in the abdomen known as visceral fat, which has been linked to higher risks of conditions including diabetes and heart disease.

Jacob Earp, an assistant professor of kinesiology at the University of Connecticut, said sex hormones appear to play a role in this redistribution.

"As men and women age, there's an unhealthy redistribution of fat from the more innocuous regions into the visceral compartment," Earp said, adding, "There is a direct link between sex hormones and fat distribution throughout the body."

Earp and colleagues tested whether adding topical testosterone therapy to rehabilitation could influence fat distribution after hip fracture. The study tracked 66 women aged 65 and older who were recovering from a recent hip fracture. All participants completed a structured exercise program, and one group also received a testosterone gel.

After six months, follow-up body-composition scans found overall body fat levels were similar between groups, but fat distribution differed: women who used the testosterone gel had lower visceral fat levels, while the group that did not receive the hormone showed an increase in visceral fat.

The findings were published in the journal Obesity Pillars. Researchers said the results suggest hormone treatment combined with exercise could be a potential strategy to improve metabolic health during recovery, though broader studies would be needed to confirm benefits and assess risks.

Ohun tí àwọn ènìyàn ń sọ

Initial reactions on X are limited and mostly neutral, consisting of summaries highlighting the study's finding that testosterone gel combined with exercise may prevent visceral fat gain in older women recovering from hip fractures, with some noting potential recovery benefits.

Awọn iroyin ti o ni ibatan

An overweight adult on a couch with a Fitbit showing low activity and GLP-1 medication nearby, illustrating study findings on reduced physical activity.
Àwòrán tí AI ṣe

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

Adults with obesity who began taking GLP-1 receptor agonist medications showed declines in Fitbit-measured physical activity after starting treatment, according to a retrospective study presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

Researchers at Vanderbilt Health discovered that both popular weight loss drugs and bariatric surgery significantly reduce fat mass while causing modest losses in fat-free mass, including muscle, in patients with obesity. The findings, based on over 3,000 patients, show improvements in overall body composition over 24 months. Maintaining this balance is crucial for long-term health, the study emphasizes.

Ti AI ṣe iroyin

New research from Turkey shows that men with obesity tend to develop more abdominal fat and liver stress, while women exhibit higher inflammation and cholesterol levels. These findings, presented at the European Congress on Obesity in Istanbul, highlight sex-based differences that could inform personalized treatments. The study analyzed patients treated between 2024 and 2025.

Researchers at the University of Pennsylvania used artificial intelligence to analyze more than 400,000 Reddit posts about GLP-1 medications such as semaglutide and tirzepatide, identifying frequently discussed symptoms—including menstrual changes and temperature-related complaints—that may be less prominent in clinical trial reporting and drug labeling.

Ti AI ṣe iroyin

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ